<DOC>
	<DOCNO>NCT00414856</DOCNO>
	<brief_summary>This study ass safety tolerability oral single dose application AFQ056 GERD patient .</brief_summary>
	<brief_title>Effects AFQ056 Baclofen Meal-Induced Gastroesophageal Reflux</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<criteria>Male female patient GERD ( 1860 year ) history moderate severe reflux symptom ( heartburn acid regurgitation 2 days/week , and/or nighttime reflux , and/or meal reflux ) ≥ 3 month : uncomplicated refluxesophagitis degree evidence esophagogastroduodenoscopy ( EGD ) within last 12 month , OR ( ) pathological ambulatory 24hours pH measurement within last 12 month pH &lt; 4 ≥ 9 % time . Females must child bear potential ( postmenopausal woman regular menstrual bleeding least 1 year woman surgically sterilize least 6 month prior ) . Menopause confirm plasma FSH level 37.0 – 185.0 mIU/mL . Surgical sterilization procedure must support clinical documentation . Patients must able completely finish highfat breakfast within 15 minute . Body mass index must 30 . Patients must weigh least 60 kg participate study . Patients must able communicate well investigator , understand comply requirement study understand sign write informed consent . History : Upper gastrointestinal ( GI ) surgery radiation GI disorder GERD may significantly affect incidence and/or assessment reflux episode ( GI motility disorder , connective tissue disease like scleroderma , Barrett ’ esophagus , hiatal hernia &gt; 34 cm , previous esophageal bleeding , esophageal varix , active gastric duodenal ulcer disease , active esophagitis Delayed gastric emptying , endoscopic indication delay gastric empty gastric outlet obstruction . Neurologic/psychiatric disorder include family history epilepsy clinically significant cardiac disease Diabetes mellitus metabolic disorder include hyperlipidemia require treatment Any significant acute chronic condition except follow treat quoted drug stable therapy least 4 week : Hypertension wellcontrolled follow : 1 . ACE inhibitor : benazepril , captopril , cilazapril , enalapril , fosinopril , imidapril , lisinopril , moexipril , perindopril tertbutylamine , quinapril , ramipril , spirapril , trandolapril , zofenopril , and/or 2. angiotensin II receptor antagonist : candesartan cilexetil , eprosartan , irbesartan , losartan , olmesartan , telmisartan , valsartan , and/or 3. diuretic : amiloride , bendroflumethiazide , bumetanide , canrenoate de potassium , chlortalidone , cicletanine , clopamide , cyclothiazide , furosemide , hydrochlorothiazide , indapamide , methyclothiazide , piretanide , spironolactone , torasemide , triamterene , xipamide , and/or 4. calcium antagonist : bepridil , felodipine , isradipine , lercanidipine , manidipine , nimodipine , nitrendipine , amlodipine , nicardipine BUT NOT diltiazem , nifedipine , verapamil Wellcompensated asthma topical use corticosteroid and/or β2mimetics Patients thyroid hormone therapy normal TSH value . Nonsteroidal antiinflammatory drug include aspirin use week prior treatment/impedance monitoring . Patients body mass index ≥ 30 . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>GERD</keyword>
	<keyword>gastroesophageal reflux disease</keyword>
	<keyword>meal-induced gastroesophageal reflux event</keyword>
</DOC>